Navigation Links
New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population
Date:9/1/2011

WASHINGTON, Sept. 1, 2011 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive.  The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.  

Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) mutation. According to the FDA, the mutation is only present in 1-7% of people with NSCLC, primarily those diagnosed with adenocarcinoma.

"This is exciting news," said LCA President & CEO, Laurie Fenton Ambrose.  "Personalized medicine is where we are headed for lung cancer treatments.  This is one of the first steps towards identifying medications that help select populations of people.  We must continue to identify other mutations and find drugs that treat them to finally see cures for lung cancer." 

"I was enrolled in the phase I trial for this drug," said Linnea Duff, NH resident and longtime lung cancer survivor.  "At the time I began the trial, I was hoping to have my life extended for a few months. Instead, I got three more years to spend with my family and friends. In addition, because this was a targeted therapy, the side effects were minimal and my quality of life during this time has been remarkable."

Xalkori has shown a life changing response to lung cancer in those patients who are ALK positive.  Lung Cancer Alliance encourages lung cancer patients to discuss genetic testing options with their health care team.  

It is important to note that many genetic mutations have been identified but not all have drugs to target the mutations at this time. With continued focus from researchers and increased participation in clinical trials, more and more of these personalized therapies will become available.  

For more information about clinical trials, please call the Lung Cancer Clinical Trial Matching Service, 800-698-0931.

Lung Cancer Alliance is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer.  Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance  

Media Contact:
Kay Cofrancesco
kay@lungcanceralliance.org
202-463-2080


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unapproved Emergency Birth Control Medicine Possibly in U.S. Distribution May Be Ineffective and Unsafe
2. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
3. Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
4. Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
5. TandemHeart Approved for Expanded Reimbursement
6. Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List
7. Laureates Electronic Submission Gateway Approved
8. Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
9. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
10. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
11. FDA Expands Approved Use For Carotid Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the ... in the Washington D.C. metropolitan area. ... delivery of medications through the convenience of its patient-friendly mobile ... within one hour to any location in D.C. ... invaluable service to Washington D.C. ," says ...
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today ... for active, healthy lifestyles and highlighting the importance of proactive eye and ear ... and shares the latest innovations in hearing aid technology. , In this ...
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & ... assistance to communities in North-Central West Virginia, is embarking on a cooperative charity ... in the area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding ...
(Date:8/18/2017)... Humble, TX (PRWEB) , ... August 18, 2017 ... ... insurance management and financial planning firm that serves residential and commercial clients in ... a charity drive to raise community support for the fight against cancer. , ...
(Date:8/18/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has released ... pertaining to the mother of the Savior whom the world calls “Mother Mary”. Yisrayl says ... the role of this historical woman. , “The world bows, kisses the feet of, ...
(Date:8/18/2017)... ... , ... “Our Mountains to Climb: A Journey of Love and Faith Through ... through the faith they shared to overcome struggles in life. “Our Mountains to Climb: ... Barbara J. Corcoran, a retired teacher and happily married since 1999; the author’s personal ...
Breaking Medicine News(10 mins):